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Abstract: This paper explores the effect of granulocyte colony-stimulating factor (G-CSF) 
on mouse myocardial microvascular endothelial cell (CMECs) proliferation. CMECs were 
harvested  from  C57/BL6  mice.  CMECs  were  cultured  in  medium  containing  G-CSF 
(0 ng/mL, 20 ng/mL, 40 ng/mL, 60 ng/mL) for five days. Proliferative activity of CMECs 
was examined by CCK-8 method. Hypoxia inducible factor-1 (HIF-1) and p53 expression 
levels was determined from the mRNA obtained by reverse transcription polymerase chain 
reaction (RT-PCR). Results showed that the purity quotient of the CMECs, which were 
cultured by the method of modified myocardial tissue explant culture, was higher than 
95%. Compared with control untreated cells, the proliferative activity of CMECs and the 
expression  level  of  HIF-1  mRNA  in  these  cells  were  enhanced  by  G-CSF  treatment, 
whereas the expression level of p53 mRNA was markedly reduced. It may be concluded 
that G-CSF could promote the proliferative activity of CMECs, which might be mediated 
by upregulation of HIF-1 and downregulation of p53. 
Keywords: myocardial microvascular endothelial cell; G-SCF; Hypoxia inducible factor 1; 
p53 mRNA; HIF-1 mRNA 
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1. Introduction 
Granulocyte colony-stimulating factor (G-CSF) is a hormone produced by the body that stimulates 
the bone marrow to produce more white blood cells. G-CSF is also produced as a drug. Studies have 
found that G-CSF injections reduce the severity and duration of neutropenia in patients with some 
types  of  cancer.  G-CSF  has  also  been  applied  to  therapeutic  angiogenesis  induction  in  animal 
models [1–5] and humans [6–11]. The mechanisms for the angiogenic effects of G-CSF are partly 
attributable  to  increased  numbers  of  myelomonocytic  cells  in  the  circulation  and  their  release  of 
VEGF, in addition to the mobilization of endothelial progenitor cells [12]. Cardiac angiogenesis is 
crucially involved in the adaptive mechanism of cardiac hypertrophy and p53 accumulation is essential 
for  the  transition  from  cardiac  hypertrophy  to  heart  failure.  Pressure  overload  initially  promoted 
vascular growth in the heart by hypoxia-inducible factor-1 (Hif-1)-dependent induction of angiogenic 
factors, and inhibition of angiogenesis prevented the development of cardiac hypertrophy and induced 
systolic dysfunction. Sustained pressure overload induced an accumulation of p53 that inhibited Hif-1 
activity and thereby impaired cardiac angiogenesis and systolic function. These results indicate that the 
anti-angiogenic property of p53 may have a crucial function in the transition from cardiac hypertrophy 
to heart failure [13]. We suppose that G-CSF may stimulate myocardial microvascular endothelial cell 
proliferation through modulating HIF-1 and p53 expression. 
In the present study, we cultured a mouse myocardium microvascular endothelial cell line (CMECs) 
and  sought  to  examine  the  effect  of  G-CSF  on  CMEC  proliferation.  Then,  we  investigated  the 
mechanism  of  G-CSF  in  promoting  CMEC  proliferation  and  angiogenesis  through  examining  the 
effect of G-CSF on p53 and HIF-1 mRNA expression. Our study provides a new view and theoretical 
basis for clinical therapy of heart disease. 
2. Materials and Methods 
2.1. Materials 
Culture medium, fetal calf serum (FCS), glutamine and antibiotics were from Gibco BRL (Paisley, 
UK); EC growth supplement, gelatin, trypsin, amphotericin B and hydrocortisone were from Sigma 
(Poole,  UK);  RNA-tocDNA  Kit,  Avidin  Biotin  Complex  were  purchased  from  Nanjing  JianChen 
bioengineering  institute.  Dulbecco’s  modified  Eagle’s  medium  (DMEM)  was  purchased  from 
Invitrogen, Carlsbad, CA, USA. RNAzol B was purchased from Biogenesis Ltd (Bournemouth, UK); 
Mouse murine leukemia virus reverse transcriptase was purchased from Gibco BRL (Gaithersburg, 
MD, USA). A Cell Counting Kit-8 was purchased from Dojindo Laboratories (Kumamoto, Japan). 
2.2. Mice Myocardical Microvascular Endothelial Cell Cultures  
Hearts  were  excised  from  10–12-week-old  mice  (n = 44)  under  aseptic  conditions.  Cardiac 
ventricles  were  cleaned  by  sterilized  Hank's  solution  and  then  cut  into  pieces.  A  homogenate  of 
ventricles was suspended and filtered by sequential 200 μm and 60 μm microfiltration. The filtered 
cells were cultured in culture flasks (75 cm
2) at 37 ° C in a humidified atmosphere with 5% CO2 in 
endothelial  cell  growth  medium  (ECGM),  as  supplied  by  the  manufacturer,  supplemented  with Int. J. Mol. Sci. 2011, 12                       
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10 ng/mL  human  recombinant  epidermal  growth  factor,  1  μg/mL  hydrocortisone,  50  μg/mL 
gentamicin, 50 μg/mL amphotericin B, 12 μg bovine brain extract and 2% v/v fetal calf serum (FCS) 
for three days. 
2.3. Proliferation Assay 
The CMECs were plated in collagen-coated 24-well plates (10
4 cells/well) and cultured in DMEM 
growth medium. Then, different concentrations of G-CSF (control, 20 ng/mL, 40 ng/mL, 60 ng/mL) 
were added to the cells and the cells were incubated.  Cell viability and proliferation assays were 
performed  by  using  the  Cell  Counting  Kit-8  (CCK8;  Dojindo,  Kumamoto,  Japan)  or  trypan  blue 
staining, according to the manufacturer’s protocol. Briefly, after treatment, a 10 μL of CCK-8 solution 
was added to each well. After incubation at 37 ° C for 2 h in a humidified CO2 incubator, absorbance at 
450  nm  was  monitored  with  the  SpectraMax  Plus  384  microplate  reader  (Molecular  Devices, 
Sunnyvale,  CA,  USA).  It  should  be  1000–1500  cells/100  μL  when  culturing  cells.  After  5  days  of 
incubation, it will be 2000–3000 cells/100 μL. 
2.4. Reverse Transcription and Polymerase Chain Reaction (RT-PCR) 
Total RNA samples were prepared from cultured CMECs (2–3 days) in exponential phase using the 
TRIzol reagent (Invitrogen), according to the manufacturer’s protocol. To eliminate genomic DNA, 
10 μg of total RNA was treated with TurboDNase (Ambion) for 30 min at 37 ° C. RNA integrity  
and  quality  were  assessed  by  electrophoresis,  and  1  μg  of  the  DNase-treated  RNA  was  then  
reverse  transcribed  into  cDNA  using  a  High  Capacity  RNA-tocDNA  Kit  (Applied  Biosystems).  
The following gene-specific primers were used: GAPDH-F: 5'-GGAAAGCTGTGGCGTGATGG-3',  
GAPDH-R:  5'-GTAGGCCATGAGGTCCACCA-3';  p53-F:  5'-GCTGAGTATCTGGACGACA-3', 
p53-R:  5'-CAGGCACAAACACGAACC-3';  HIF-1-F:  5'-GTGATGGACAGGGTATGG-3',  
HIF-1-R: 5'-GGAGAAGAGCGGTTGTAT-3'. Each cycle consisted of denaturation (30 s at 94 ° C), 
annealing (30 s at 60 ° C), and elongation (30 s at 72 ° C). PCR products were subjected to 2% agarose 
gel electrophoresis. 
2.5. Statistics 
All data are presented as mean ±  standard error (SE). The standard unpaired Student's t-test was 
used to analyze significant differences among the data. 
3. Results 
3.1. CMECs Morphology and Identification 
Endothelial cells were present around myocardium tissue after two days of incubation. These cells 
exhibited a megagon or spindle shape. On the second and third day, more and more endothelial cells 
were observed around the myocardium tissue mass. After removing the tissue mass, endothelial cells 
were cultured for another 2–3 days. These cells displayed a megagon or spindle shape or rather an 
elongated shape (Figure 1). Int. J. Mol. Sci. 2011, 12                       
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The  endothelial  cell  phenotype  was  confirmed  by  acetylated  LDL  uptake,  Factor  VIII-Rag 
immunocytochemical  staining.  Results  showed  that  the  purity  of  CMECs  was  higher  than  95% 
(Figure 2).  
Figure 1. Myocardium microvascular endothelial cells (scale bar: 60 μm, 200× ). 
 
 
Figure  2.  Immunocytochemistry  Avidin  Biotin  Complex  staining  of  myocardium 
microvascular endothelial cells (scale bar: 120 μm, 100× ). 
 
3.2. CMEC Proliferative Capacity 
The proliferative capacity of CMECs in medium containing G-CSF was significantly (P < 0.05; 
P < 0.01) higher than in control medium. At 40 ng/mL G-CSF, the proliferative capacity was highest. 
Significant statistical difference (P < 0.05; P < 0.01) was observed between groups (Figure 3).  Int. J. Mol. Sci. 2011, 12                       
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Figure 3. Myocardium microvascular endothelial cell proliferation. Data are mean ±  SEM 
from  ten  independent  experiments  and  each  experiment  was  an  average  of  triplicate 
measures. * P < 0.05, ** P < 0.01, compared with control (0 ng/mL G-CSF); 
## P < 0.01, 
compared with group (40 ng/mL G-CSF).  
 
3.3. HIF-1 and p53 mRNA Expression 
Compared with control cells, the HIF-1 mRNA expression level of CMECs in medium containing  
G-CSF was markedly (P < 0.01) increased (Figure 4). The HIF-1 mRNA expression level was the 
highest  at  40  ng/mL  G-CSF,  and  was  significantly  (P < 0.01)  higher  than  that  in  the  other  two 
treatment groups (20 ng/mL and 60 ng/mL) (Figure 4). 
Compared with the control cells, the p53 mRNA expression level of CMECs in medium containing 
G-CSF was markedly (P < 0.01) decreased (Figure 5). At 40 ng/mL G-CSF, p53 mRNA expression 
level was lowest. p53 expression level observed in the group with 40 ng/mL G-CSF treatment was 
significantly (P < 0.01) lower than that in other two groups (20 ng/mL and 60 ng/mL) (Figure 5). 
Figure  4.  HIF-1  mRNA  expression.  ** P < 0.01,  compared  with  control; 
## P < 0.01, 
compared with group (40 ng/mL). Top panel: RT-PCR analysis of mRNA expression of 
HIF-1  and  GAPDH  control;  bottom  panel:  Quantification  is  the  ratio  of  gray  scale  in 
band 1 (HIF-1) to gray scale in band 2 (GAPDH). Quantification for HIF-1. 
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Figure  5.  p53  mRNA  expression.  ** P < 0.01,  compared  with  control; 
## P < 0.01, 
compared with group (40 ng/mL). Top panel: RT-PCR analysis of mRNA expression of 
p53 and GAPDH control; bottom panel: Quantification is the ratio of gray scale in band 1 
(p53) to gray scale in band 2 (GAPDH). Quantification for p53. 
 
4. Discussion 
Previous  findings  have  demonstrated  the  safety  and  feasibility  of  G-CSF  treatment  in  patients 
suffering from late revascularized STEMI in a prospective, randomized, placebo-controlled analysis. 
G-CSF was not superior to placebo regarding improvement of global as well as regional myocardial 
function [14]. Another trial demonstrated significant increase of myocardial perfusion in the short-term. 
Several  stem-cell  populations,  which  are  considered  to  improve  myocardial  regeneration  or 
neovascularization, are significantly mobilized by G-CSF [15].  
Angiogenesis, the formation of new capillaries from preexisting vessels, plays an essential role in 
development and pathological conditions such as wound healing, tumor growth and metastasis, and 
revascularization of the myocardium following myocardial infarction (MI) [16]. Formation of new 
blood vessels is critical for supplying the healing infarcted myocardium with oxygen and nutrients to 
sustain  metabolism.  Myocardial  angiogenesis  and  improved  myocardial  function  are  keys  to  cure 
cardiac disease. Therefore, to obtain pure microvascular endothelial cells, it is important to establish a 
microvascular endothelial cell culture system. Isolation and culture of microvascular endothelial cells 
has  been  difficult  due  mainly  to  small  initial  yields  and  overgrowth
 of  contaminating  cells  [17]. 
Therefore, in previous studies, endothelial cells from large vessels, e.g. human umbilical venous or 
aorta endothelial cells, were often used [18,19]. Because of obvious organ and tissue specificity, it is 
difficult to perform a more objective and accurate evaluation of pathological changes in microvascular 
endothelial cells through studying aorta endothelial cells. Therefore, it is useful to establish an in vitro 
microvascular endothelial cell culture system. In this study, we cultured myocardial microvascular 
endothelial cells and examined the purity using VIII related antigen immunohistochemical staining. 
Results  showed  that  the  purity  of  our  microvascular  endothelial  cell  culture  was  95%,  indicating 
that an  in  vitro  microvascular  endothelial  cell  culture  system  was  successfully  established.  These 
microvascular  endothelial  cells  may  be  used  for  cardiovascular  disease  therapy  and  clinical 
medicine research. Int. J. Mol. Sci. 2011, 12                       
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Endothelial cell proliferation is necessary for the formation of new vasculature. Cell proliferation 
can  be  negatively  affected  by  two  mechanisms:  enhanced  apoptosis  and  cell  cycle  progression 
arrest [20].  In  this  study,  we  tested  the  effect  of  various  concentration  of  G-CSF  on  myocardium 
microvascular  endothelial  cells  proliferation.  We  observed  that  addition  of  G-CSF  increased  the 
CMEC’s proliferative capacity. Result showed that CMEC’s proliferative capacity was the highest in 
the medium containing 40 ng/mL G-CSF. The  mechanism was unclear. However, this study may 
provide the technology basis for future research of some related diseases. RT-PCR analysis showed 
that expression levels of HIF-1 and p53 mRNA were higher in the group treated with 40 ng/mL G-CSF 
than with the other two tested concentrations (20 ng/mL or 60 ng/mL). This indicated that 40 ng/mL 
G-CSF was the most effective dose for CMEC proliferation. 
Hypoxia  inducible  factor-1  (HIF-1)  is  a  potent  α,  β  transcription  factor  that  mediates  tissue 
responses  to  hypoxia.  Once  activated,  the  heterodimer  binds  to  the  DNA  consensus  sequence  
5′-RCGTG-3′,  driving  transcription  of  many  genes  involved  in  oxygen  homeostasis,  including 
inducible  nitric  oxide  synthase  (iNOS),  vascular  endothelial  growth  factor  (VEGF),  and  heme 
oxygenase-1  (HO-1)  [21–24].  It  is  well  known  that  p53  plays  an  important  role  in  controlling 
angiogenesis  by  different  mechanisms,  including  regulation  of  vascular  endothelial  growth  factor 
(VEGF) expression. Narasimhan et al. [25] reported that a mutant-type p53 could enhance VEGF 
expression induced by 12-O-tetradecanoylphorbol-13-acetate by activating protein kinase C. Cadwell 
and Zambetti [26] showed that wild-type p53 down-regulates VEGF promoter activity. This study 
showed that G-CSF treatment increased the HIF-1 mRNA expression level and reduced p53 mRNA 
expression in CMECs. G-CSF was significantly associated with VEGF expression. We suppose that  
G-CSF  promoted  angiogenesis  partly  through  modulating  HIF-1  mRNA  expression,  subsequently 
heightening  cardiovascular  compensation  capacity.  In  addition,  G-CSF  still  enhances  CMEC’s 
proliferative capacity possibly partly through modulating p53 mRNA expression. We have searched a 
lot of relevant literature and do not find research regarding protein expression of p53 and HIF-1 in 
other systems. These hypotheses will be tested in future studies. Of course, a concrete mechanism still 
needs to be investigated in future studies. 
5. Conclusion 
In  conclusion,  our  study  showed  that  G-CSF  promoted  CMEC  proliferation,  possibly  through 
modulating HIF-1 and p53 mRNA expression. This experimental data might provide a useful indicator 
of prognosis and therapy in heart diseases.  
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